CEP-32496

Showing 1 posts of 1 posts found.

Teva image

Teva and Ignyta shake hands in oncology deal

March 19, 2015
Research and Development, Sales and Marketing CEP-32496, CEP-40125, Levact, RXDX-105, Teva, ignyta, oncology

Ignyta has acquired four oncology R&D assets from Israeli pharma generics giant Teva in a deal worth around $42 million. …

The Gateway to Local Adoption Series

Latest content